title: AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
abstract: The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen. This was a retrospective, multi-center cohort study of all HIV-1-infected patients diagnosed with BL/BLL between 1990 - 2004. Patients were assigned to two different chemotherapy approaches. Group A received a protocol which was adapted from the German multi-center study group for adult acute lymphoblastic leukemia (GMALL). Group B received a conventional CHOP-based chemotherapy. Fifty-one patients were included in the analysis. In group A (n = 20), significantly more patients achieved complete remission (75% vs 40%, P = 0.02) than in group B (n = 31). One-year survival in group A was 65% compared to 44% in group B (P = 0.17). In a multi-variable Cox regression analysis, treatment according to the GMALL protocol was significantly associated with prolonged survival with a relative hazard rate of 0.13 (95% CI 0.03 - 0.63, P = 0.01). In conclusion, the short and intensive GMALL protocol for B-ALL/NHL is feasible in patients with AIDS-BL/BLL. Outcome may be improved compared to patients treated with CHOP-based regimens. In the era of HAART, more intensive chemotherapy regimens should be considered in patients with highly aggressive lymphomas.
authors.affiliation: University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany. hoffmann@ifi-infektiologie.de
authors.forename: Christian
authors.initials: C
authors.lastname: Hoffmann
authors.forename: Eva
authors.initials: E
authors.lastname: Wolf
authors.forename: Christoph
authors.initials: C
authors.lastname: Wyen
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Jan
authors.initials: J
authors.lastname: Van Lunzen
authors.forename: Hans-Juergen
authors.initials: HJ
authors.lastname: Stellbrink
authors.forename: Albrecht
authors.initials: A
authors.lastname: Stoehr
authors.forename: Andreas
authors.initials: A
authors.lastname: Plettenberg
authors.forename: Hans
authors.initials: H
authors.lastname: Jaeger
authors.forename: Richard
authors.initials: R
authors.lastname: Noppeney
authors.forename: Marcus
authors.initials: M
authors.lastname: Hentrich
authors.forename: Nicola
authors.initials: N
authors.lastname: Goekbuget
authors.forename: Dieter
authors.initials: D
authors.lastname: Hoelzer
authors.forename: Heinz-August
authors.initials: HA
authors.lastname: Horst
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000821:virology; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy* / Q000821:virology; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D011241:Prednisone; D003630:Daunorubicin